Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML. Metabolomics, the global profiling of small molecules in a biological sample, has emerged in the last decade as an important tool for studying the metabolic dependency of cancer cells. Metabolic reprogramming is not only an important manifestation of AML but clinically relevant for diagnosis, risk stratification and targeted drug development. In this review, we discuss notable metabolic studies of the last decade and their application to novel therapies.

急性髓细胞性白血病（AML）是一种复杂的异质血液恶性病，由骨髓分化和增殖的突变引起。根据染色体和分子畸变，对治疗的反应和长期结果差异很大。许多平台已被用于表征和分层AML。代谢组学是生物样品中小分子的全球概况，在过去的十年中已成为研究癌细胞代谢依赖性的重要工具。代谢重编程不仅是AML的重要表现，而且在临床上与诊断，风险分层和靶向药物开发有关。在这篇综述中，我们讨论了近十年来著名的代谢研究及其在新疗法中的应用。